MA30723B1 - Benzoxazoles et oxazolopyridines utiles en tant qu'inhibiteurs des janus kinases. - Google Patents
Benzoxazoles et oxazolopyridines utiles en tant qu'inhibiteurs des janus kinases.Info
- Publication number
- MA30723B1 MA30723B1 MA31738A MA31738A MA30723B1 MA 30723 B1 MA30723 B1 MA 30723B1 MA 31738 A MA31738 A MA 31738A MA 31738 A MA31738 A MA 31738A MA 30723 B1 MA30723 B1 MA 30723B1
- Authority
- MA
- Morocco
- Prior art keywords
- disease
- treatment
- compounds
- formula
- oxazolopyridines
- Prior art date
Links
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 title 1
- 102000015617 Janus Kinases Human genes 0.000 title 1
- 108010024121 Janus Kinases Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 5
- 238000011282 treatment Methods 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 4
- -1 2,7-disubstituted benzazole Chemical class 0.000 abstract 2
- 241001465754 Metazoa Species 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 2
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 abstract 1
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 abstract 1
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
L'INVENTION CONCERNE DES COMPOSÉS 2,7-DISUBSTITUÉS BENZOXAZOLE ET 2,4-DISUBSTITUÉS OXAZOLO[5,4- C]PYRIDINE SELON LA FORMULE I ÉNONCÉE CI-DESSOUS, AINSI QUE LEURS SELS, LEURS PROCÉDÉS DE PRÉPARATION, LEUR MISE EN PRATIQUE DANS UN PROCÉDÉ DESTINÉ AU TRAITEMENT DU CORPS HUMAIN OU ANIMAL, L'UTILISATION DE CES COMPOSÉS DANS LE TRAITEMENT (Y COMPRIS LA PROPHYLAXIE) DU CORPS ANIMAL ET, PLUS PARTICULIÈREMENT, DU CORPS HUMAIN (PARTICULIÈREMENT EN RAPPORT AVEC UNE MALADIE PROLIFÉRANTE), LEUR UTILISATION, SEULS OU EN COMBINAISON AVEC UN OU PLUSIEURS COMPOSÉS PHARMACEUTIQUEMENT ACTIFS, POUR LE TRAITEMENT, EN PARTICULIER, D'UNE MALADIE INDUITE PAR LA PROTÉINE-TYROSINE KINASE (TELLE QU'UNE MALADIE TUMORALE) OU LA FABRICATION D'UNE PRÉPARATION PHARMACEUTIQUE DESTINÉE À ÊTRE UTILISÉE DANS LE TRAITEMENT D'UNE TELLE MALADIE, UN PROCÉDÉ DESTINÉ AU TRAITEMENT D'UNE TELLE MALADIE ET UNE PRÉPARATION PHARMACEUTIQUE DESTINÉE AU TRAITEMENT D'UNE MALADIE TELLE QUE MENTIONNÉE. LES COMPOSÉS SONT DÉCRITS PAR LA FORMULE I, LES SYMBOLES DE CETTE FORMULE ÉTANT TELS QUE DÉFINIS DANS LA DESCRIPTION. LES COMPOSÉS INHIBENT, PAR EXEMPLE, JAK2 ET JAK3.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06120733A EP1900729A1 (fr) | 2006-09-15 | 2006-09-15 | Benzoxazoles et oxazolopyridines et leur utilisation comme inhibiteurs de Janus kinases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA30723B1 true MA30723B1 (fr) | 2009-09-01 |
Family
ID=37717673
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA31738A MA30723B1 (fr) | 2006-09-15 | 2009-03-30 | Benzoxazoles et oxazolopyridines utiles en tant qu'inhibiteurs des janus kinases. |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US8629168B2 (fr) |
| EP (2) | EP1900729A1 (fr) |
| JP (1) | JP5325105B2 (fr) |
| KR (1) | KR20090064389A (fr) |
| CN (1) | CN101516860B (fr) |
| AR (1) | AR062786A1 (fr) |
| AT (1) | ATE532774T1 (fr) |
| AU (1) | AU2007296916B2 (fr) |
| BR (1) | BRPI0716841A2 (fr) |
| CA (1) | CA2660987A1 (fr) |
| CL (1) | CL2007002669A1 (fr) |
| CO (1) | CO6150142A2 (fr) |
| CR (1) | CR10639A (fr) |
| EA (1) | EA200900388A1 (fr) |
| ES (1) | ES2377148T3 (fr) |
| GT (1) | GT200900056A (fr) |
| IL (1) | IL196860A0 (fr) |
| MA (1) | MA30723B1 (fr) |
| MX (1) | MX2009002812A (fr) |
| NO (1) | NO20091469L (fr) |
| PA (1) | PA8748101A1 (fr) |
| PE (1) | PE20080842A1 (fr) |
| PL (1) | PL2066647T3 (fr) |
| PT (1) | PT2066647E (fr) |
| SM (1) | SMP200900023B (fr) |
| TN (1) | TN2009000070A1 (fr) |
| TW (1) | TW200819444A (fr) |
| UY (1) | UY30587A1 (fr) |
| WO (1) | WO2008031594A1 (fr) |
| ZA (1) | ZA200900477B (fr) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110160232A1 (en) | 2007-10-04 | 2011-06-30 | Pingda Ren | Certain chemical entities and therapeutic uses thereof |
| US8993580B2 (en) | 2008-03-14 | 2015-03-31 | Intellikine Llc | Benzothiazole kinase inhibitors and methods of use |
| MX2011000216A (es) | 2008-07-08 | 2011-03-29 | Intellikine Inc | Inhibidores de cinasa y metodos para su uso. |
| BRPI0915781A2 (pt) * | 2008-07-15 | 2015-11-10 | Sanofi Aventis | oxazolopiridimas como agonista do receptor edg-1 |
| WO2010018874A1 (fr) * | 2008-08-12 | 2010-02-18 | Takeda Pharmaceutical Company Limited | Composé amide |
| US8476431B2 (en) | 2008-11-03 | 2013-07-02 | Itellikine LLC | Benzoxazole kinase inhibitors and methods of use |
| AU2009320683B2 (en) | 2008-11-28 | 2012-07-19 | Kowa Company, Ltd. | Pyridine-3-carboxyamide derivative |
| EP2518054A1 (fr) | 2009-12-24 | 2012-10-31 | Takeda Pharmaceutical Company Limited | Composé amide |
| AR079980A1 (es) * | 2010-01-13 | 2012-03-07 | Sanofi Aventis | Derivados de oxazolopirimidina sustituida en 2,5,7 |
| JP6130305B2 (ja) | 2011-02-23 | 2017-05-17 | インテリカイン， エルエルシー | キナーゼ阻害剤の組み合わせおよびそれらの使用 |
| US8907093B2 (en) * | 2011-07-07 | 2014-12-09 | Sanofi | Carboxylic acid derivatives having an oxazolo[4,5-c]pyridine ring |
| US8580816B2 (en) * | 2011-07-07 | 2013-11-12 | Sanofi | Carboxylic acid derivatives having an oxazolo[5,4-b]pyridine ring |
| CN103102359B (zh) * | 2011-11-15 | 2016-11-09 | 江苏先声药业有限公司 | 嘧啶类化合物及其应用 |
| CN104185420B (zh) | 2011-11-30 | 2017-06-09 | 埃默里大学 | 用于治疗或预防逆转录病毒和其它病毒感染的抗病毒jak抑制剂 |
| WO2014075318A1 (fr) * | 2012-11-19 | 2014-05-22 | 江苏先声药业有限公司 | Composés de pyrimidine et utilisation associée |
| WO2014153509A1 (fr) | 2013-03-22 | 2014-09-25 | Millennium Pharmaceuticals, Inc. | Combinaison d'inhibiteurs catalytiques de mtorc1/2 et inhibiteurs sélectifs de la kinase aurora a |
| CN103664759A (zh) * | 2013-12-06 | 2014-03-26 | 常熟市联创化学有限公司 | 一种3-羟基-2-硝基吡啶的制备方法 |
| NZ723940A (en) | 2014-02-03 | 2017-12-22 | Quadriga Biosciences Inc | Beta-substituted beta-amino acids and analogs as chemotherapeutic agents |
| CN106132406B (zh) | 2014-02-03 | 2020-03-27 | 夸德里加生物科学公司 | 作为化疗剂的β-取代的γ-氨基酸和类似物 |
| WO2016047678A1 (fr) * | 2014-09-25 | 2016-03-31 | 武田薬品工業株式会社 | Composé hétérocyclique |
| WO2017024009A1 (fr) | 2015-08-03 | 2017-02-09 | Quadriga Biosciences, Inc. | Acides bêta-aminés substitués en bêta et analogues à utiliser en tant qu'agents de chimiothérapie et leurs utilisations |
| US20220372135A1 (en) | 2019-09-27 | 2022-11-24 | Disc Medicine, Inc. | Methods for treating myelofibrosis and related conditions |
| CA3177830A1 (fr) | 2020-05-13 | 2021-11-18 | Maria BECONI | Anticorps anti-hemojuveline (hjv) pour le traitement de la myelofibrose |
| TW202307005A (zh) | 2021-05-28 | 2023-02-16 | 美商邊際分析公司 | 以核醣體蛋白質S6激酶α-1 (RSK1)及核醣體蛋白質S6激酶α-3 (RSK2)之調節劑治療神經病症之方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1382339E (pt) * | 1999-12-10 | 2008-02-06 | Pfizer Prod Inc | Composições que contêm derivados de pirrolo[2,3-d]- pirimidina |
| SE0301373D0 (sv) * | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Novel compounds |
| DE10344223A1 (de) * | 2003-09-24 | 2005-04-21 | Merck Patent Gmbh | 1,3-Benzoxazolylderivate als Kinase-Inhibitoren |
| GB0402140D0 (en) * | 2004-01-30 | 2004-03-03 | Smithkline Beecham Corp | Novel compounds |
| EP1674467A1 (fr) * | 2004-12-22 | 2006-06-28 | 4Sc Ag | Derives benzazoles 2,5- et 2,6-disubstitues utiles comme des inhibiteurs de la proteine kinase |
| ES2359431T3 (es) * | 2005-09-02 | 2011-05-23 | F. Hoffmann-La Roche Ag | Derivados de benzooxazol, oxazolopiridina, benzotiazol y tiazolopiridina. |
| WO2008009458A1 (fr) * | 2006-07-21 | 2008-01-24 | Novartis Ag | Composés de 2,4-di(arylamino)-pyrimidine-5-carboxamide comme inhibiteurs des jak kinases |
-
2006
- 2006-09-15 EP EP06120733A patent/EP1900729A1/fr not_active Ceased
-
2007
- 2007-09-12 UY UY30587A patent/UY30587A1/es not_active Application Discontinuation
- 2007-09-13 AU AU2007296916A patent/AU2007296916B2/en not_active Ceased
- 2007-09-13 EP EP07802300A patent/EP2066647B1/fr active Active
- 2007-09-13 PE PE2007001237A patent/PE20080842A1/es not_active Application Discontinuation
- 2007-09-13 PL PL07802300T patent/PL2066647T3/pl unknown
- 2007-09-13 CN CN2007800339907A patent/CN101516860B/zh not_active Expired - Fee Related
- 2007-09-13 AR ARP070104060A patent/AR062786A1/es unknown
- 2007-09-13 CA CA002660987A patent/CA2660987A1/fr not_active Abandoned
- 2007-09-13 KR KR1020097005248A patent/KR20090064389A/ko not_active Withdrawn
- 2007-09-13 AT AT07802300T patent/ATE532774T1/de active
- 2007-09-13 ES ES07802300T patent/ES2377148T3/es active Active
- 2007-09-13 MX MX2009002812A patent/MX2009002812A/es active IP Right Grant
- 2007-09-13 EA EA200900388A patent/EA200900388A1/ru unknown
- 2007-09-13 BR BRPI0716841-1A2A patent/BRPI0716841A2/pt not_active IP Right Cessation
- 2007-09-13 WO PCT/EP2007/007983 patent/WO2008031594A1/fr not_active Ceased
- 2007-09-13 JP JP2009527741A patent/JP5325105B2/ja not_active Expired - Fee Related
- 2007-09-13 PT PT07802300T patent/PT2066647E/pt unknown
- 2007-09-13 US US12/440,298 patent/US8629168B2/en not_active Expired - Fee Related
- 2007-09-14 CL CL200702669A patent/CL2007002669A1/es unknown
- 2007-09-14 TW TW096134606A patent/TW200819444A/zh unknown
- 2007-09-14 PA PA20078748101A patent/PA8748101A1/es unknown
-
2009
- 2009-01-21 ZA ZA200900477A patent/ZA200900477B/xx unknown
- 2009-02-02 IL IL196860A patent/IL196860A0/en unknown
- 2009-02-26 CR CR10639A patent/CR10639A/es not_active Application Discontinuation
- 2009-02-27 TN TN2009000070A patent/TN2009000070A1/fr unknown
- 2009-03-10 CO CO09024347A patent/CO6150142A2/es unknown
- 2009-03-11 GT GT200900056A patent/GT200900056A/es unknown
- 2009-03-30 MA MA31738A patent/MA30723B1/fr unknown
- 2009-04-09 SM SM200900023T patent/SMP200900023B/it unknown
- 2009-04-15 NO NO20091469A patent/NO20091469L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA30723B1 (fr) | Benzoxazoles et oxazolopyridines utiles en tant qu'inhibiteurs des janus kinases. | |
| MA33502B1 (fr) | Composés pyrazolopyrimidine inhibiteurs des jak et procédés | |
| MA63501B1 (fr) | Dérivés d'urée pouvant être utilisés pour traiter le cancer | |
| TNSN05298A1 (fr) | Derives de pyrazolo-quinazoline, procede pour leur preparation et leur utilisation comme inhibiteurs de kinases | |
| MA47399A (fr) | Dérivés de 7-phényléthylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one en tant qu'inhibiteurs de la forme mutée des protéines idh1 et idh2 | |
| MA30089B1 (fr) | (arylsulfonyl)-pyrasolopiperidines | |
| TNSN08270A1 (fr) | Dérivés pyrimidiques destinés à traiter une croissance cellulaire anormale | |
| TNSN05176A1 (fr) | Derives de diazepino-indole servant d'inhibiteurs de kinases | |
| MA28064A1 (fr) | Dérivés de pyrrolo [3,4-c] pyrazole actifs comme inhibiteurs de kinases | |
| MA52360B1 (fr) | Dérivés de 2-amino-pyridine ou de 2-amino-pyrimidine utilisés en tant qu'inhibiteurs de kinases dépendantes des cyclines | |
| MA30333B1 (fr) | Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete. | |
| MA32727B1 (fr) | Pyrazolylaminopyridines au titre d'inhibiteurs de fak | |
| MA31283B1 (fr) | Produits dérivés de 2,3-dihydroimidazo[1,2-c]quinazoline substitués, utiles pour le traitement de troubles hyperlifératifs et de maladies associées à une angiogénèse | |
| MA29378B1 (fr) | Composition pharmaceutique comprenant une diphenyluree substituee par un omega-carboxyaryle pour le traitement du cancer | |
| MA30073B1 (fr) | Derives de piperidine 3,5-substitues en tant qu'inhibiteurs de renine | |
| MA27774A1 (fr) | Inhibiteurs de phosphatidylinositol 3-kinase | |
| MA33636B1 (fr) | Dérivés aminopropioniques substitués comme inhibiteurs de néprilysine | |
| MA47079A (fr) | Composés amino-triazolopyidines et leur utilisation pour traiter le cancer | |
| TN2009000544A1 (fr) | Derives de benzimidazole | |
| MA30532B1 (fr) | Sulfonamides tricycliques condenses inhibiteurs de gamma-secretase | |
| TN2009000138A1 (fr) | Biaryl-ether-urees | |
| EP1841426A4 (fr) | Carbinamines tertiaires incluant des heterocycles substitues, agissant en tant qu'inhibiteurs de la beta-secretase et utilisees dans le traitement de la maladie d'alzheimer | |
| MA30351B1 (fr) | Composes de tetrahydropyridothienopyrimidine et leurs procedes d'utilisation | |
| MA33239B1 (fr) | 3h-imidazo [4,5-c] pyridine-6-carboxamides en tant qu'anti-inflammatoires | |
| EP1562897A4 (fr) | Inhibiteurs de beta-secretase phenylcarboxamide utilises dans le traitement de la maladie d'alzheimer |